Caspofungin Acetate
FDA-approved product (powder, intravenous), marketed as Cancidas, Caspofungin Acetate.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Aspergillosis
- Candidemia
- Candidiasis
- Fungal infectious disease
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other antimycotics for systemic use
- Anti-infective classification
- Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J02AX04
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA65.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli53.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae57.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis61.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Caspofungin Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- FurazolidoneExisting use: Other antiinfectives and antiseptics91.4% AI-predicted activityagainst M. tuberculosisLab records exist49 registered studies
- TriflupromazineExisting use: Psychosis90.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- ValdecoxibExisting use: Dysmenorrhea, Osteoarthritis, Rheumatic disease and 1 more88.6% AI-predicted activityagainst M. tuberculosisLab records exist31 registered studies
- CelecoxibExisting use: Ankylosing spondylitis, Cancer, Colorectal neoplasm and 15 more87.6% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Dorzolamide HydrochlorideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma86.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- MethazolamideExisting use: Glaucoma, Open-angle glaucoma85.6% AI-predicted activityagainst M. tuberculosisLab records exist11 registered studies
- AcetazolamideExisting use: Altitude sickness, Angle-closure glaucoma, Congestive heart failure and 5 more85.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Trifluoperazine HydrochlorideExisting use: Anxiety disorder, Mental or behavioural disorder, Psychosis and 1 more84.6% AI-predicted activityagainst M. tuberculosis1 registered study
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives84.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- NitrofurazoneExisting use: Eye infection, Leishmaniasis, Trypanosomiasis84.0% AI-predicted activityagainst M. tuberculosis8 registered studies
- BrinzolamideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma83.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- ZonisamideExisting use: Epilepsy, Focal-onset seizure, Partial epilepsy and 1 more82.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Effects and Safety of Caspofungin and Corticosteroids in Pneumocystis Pneumonia in Non-HIV Patients
NCT02603575 · start 2015-11
Registered record
- Registry ID
- NCT02603575
- Conditions
- Pneumocystis Pneumonia
- Interventions
- caspofungin; corticosteroids; Sulfanilamides
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2015-11
- Completion
- Not recorded
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPneumocystis PneumoniaInterventioncaspofungin; corticosteroids; SulfanilamidesPhaseNot applicableRegistry statusUnknownImpact of a Loading Dose of Caspofungin in Invasive Candidiasis in ICU Patients
NCT02413892 · start 2015-05
Registered record
- Registry ID
- NCT02413892
- Conditions
- Candida Infections
- Interventions
- Not recorded
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2015-05
- Completion
- 2017-02
- Enrolment
- 15
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCandida InfectionsInterventionNot recordedPhaseNot recordedRegistry statusCompletedOptimal Dosage of Caspofungin in Critically Ill Patients
NCT01994096 · start 2013-11
Registered record
- Registry ID
- NCT01994096
- Conditions
- Critically Ill; Suspected Invasive Candidiasis
- Interventions
- Caspofungin
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2013-11
- Completion
- 2015-10
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCritically Ill; Suspected Invasive CandidiasisInterventionCaspofunginPhasePhase 4Registry statusCompletedPharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure
NCT01968395 · start 2013-09
Registered record
- Registry ID
- NCT01968395
- Conditions
- Bacterial Infections and Mycoses; Liver Disease
- Interventions
- Caspofungin 70 mg
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2013-09
- Completion
- 2014-10-21
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBacterial Infections and Mycoses; Liver DiseaseInterventionCaspofungin 70 mgPhasePhase 4Registry statusCompletedShort and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents
NCT01686607 · start 2012-10-01
Registered record
- Registry ID
- NCT01686607
- Conditions
- Systemic Fungal Infections
- Interventions
- Parenteral micafungin application; Other parenteral antifungal drugs
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2012-10-01
- Completion
- 2018-04-30
- Enrolment
- 40,110
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSystemic Fungal InfectionsInterventionParenteral micafungin application; Other parenteral antifungal drugsPhaseNot recordedRegistry statusCompletedEmpirical Versus Preemptive Antifungal Therapy
NCT01288378 · start 2012-03
Registered record
- Registry ID
- NCT01288378
- Conditions
- Fungal Infection; Leukemia; Myelodysplastic Syndromes
- Interventions
- caspofungin acetate
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2012-03
- Completion
- 2019-04-04
- Enrolment
- 556
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionFungal Infection; Leukemia; Myelodysplastic SyndromesInterventioncaspofungin acetatePhasePhase 3Registry statusCompletedthe Influence of Prophylactic and Empirical Anti-fungal Treatment in Severe Sepsis Patients With Perforations
NCT02941068 · start 2012-03
Registered record
- Registry ID
- NCT02941068
- Conditions
- Intra-abdominal Perforation
- Interventions
- fluconazole and caspofungin
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2012-03
- Completion
- Not recorded
- Enrolment
- 223
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionIntra-abdominal PerforationInterventionfluconazole and caspofunginPhasePhase 2Registry statusCompletedPharmacokinetics of Caspofungin (Cancidas ®) Given Intravenously as Therapy to Patients With an Invasive Fungal Infection in the Intensive Care Unit - a Search for Co-variates
NCT01533558 · start 2012-01
Registered record
- Registry ID
- NCT01533558
- Conditions
- Invasive Fungal Infection
- Interventions
- caspofungin
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2012-01
- Completion
- 2013-06
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInvasive Fungal InfectionInterventioncaspofunginPhaseNot recordedRegistry statusCompletedPharmacokinetic, Safety and Efficacy of Intermittent Application of Caspofungin for Antifungal Prophylaxis
NCT01318148 · start 2011-04
Registered record
- Registry ID
- NCT01318148
- Conditions
- Fungal Infection
- Interventions
- caspofungin
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2011-04
- Completion
- 2013-10
- Enrolment
- 25
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionFungal InfectionInterventioncaspofunginPhasePhase 2Registry statusCompletedA Study of Caspofungin (MK-0991) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections (MK-0991-074)
NCT01165320 · start 2010-07-06
Registered record
- Registry ID
- NCT01165320
- Conditions
- Candidiasis, Esophageal; Candidiasis, Invasive; Aspergillosis
- Interventions
- Caspofungin
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2010-07-06
- Completion
- 2013-09-17
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCandidiasis, Esophageal; Candidiasis, Invasive; AspergillosisInterventionCaspofunginPhasePhase 2Registry statusCompletedValidation of an Index of Neutropenia (D-index) in Febrile Neutropenic Cancer Patients
NCT00982540 · start 2010-02
Registered record
- Registry ID
- NCT00982540
- Conditions
- Invasive Fungal Infections; Invasive Aspergillosis; Invasive Fusariosis
- Interventions
- caspofungin as preemptive antifungal therapy
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Terminated
- Start
- 2010-02
- Completion
- 2013-12
- Enrolment
- 28
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInvasive Fungal Infections; Invasive Aspergillosis; Invasive FusariosisInterventioncaspofungin as preemptive antifungal therapyPhaseNot applicableRegistry statusTerminatedEffect of Weight and/or Obesity on Caspofungin Drug Concentrations
NCT01062165 · start 2010-02
Registered record
- Registry ID
- NCT01062165
- Conditions
- Obesity; Fungal Infection
- Interventions
- Caspofungin
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2010-02
- Completion
- 2010-12
- Enrolment
- 18
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionObesity; Fungal InfectionInterventionCaspofunginPhasePhase 4Registry statusCompletedCaspofungin as Prophylaxis in High Risk Liver Transplantation Recipients
NCT01260974 · start 2009-05
Registered record
- Registry ID
- NCT01260974
- Conditions
- Fungemia; Mycoses
- Interventions
- Caspofungin
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Unknown
- Start
- 2009-05
- Completion
- 2012-11
- Enrolment
- 38
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionFungemia; MycosesInterventionCaspofunginPhasePhase 2Registry statusUnknownAn Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Deep Tissue Infection Due To Candida
NCT00805740 · start 2009-04
Registered record
- Registry ID
- NCT00805740
- Conditions
- Candidiasis; Fungemia
- Interventions
- Active anidulafungin; Active Caspofungin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Terminated
- Start
- 2009-04
- Completion
- 2012-06
- Enrolment
- 41
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCandidiasis; FungemiaInterventionActive anidulafungin; Active CaspofunginPhasePhase 3Registry statusTerminatedPharmacokinetics of Caspofungin in Burn Patients
NCT00748345 · start 2009-02
Registered record
- Registry ID
- NCT00748345
- Conditions
- Thermal Injury
- Interventions
- Caspofungin (drug)
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Completed
- Start
- 2009-02
- Completion
- 2010-12
- Enrolment
- 2
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionThermal InjuryInterventionCaspofungin (drug)PhasePhase 2 / Phase 3Registry statusCompleted